FindTrial
Sign In

Efficiency and tolerability of 30% new supramolecular salicylic acid for rosacea

Efficacy and skin tolerability of the addition of 30% new supramolecular salicylic acid to Minocycline for erythematotelangiectatic and papulopustular rosacea:A split-face study

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-OOH-17012560
Enrollment
Unknown
Registered
2017-09-03
Start date
2017-09-04
Completion date
Unknown
Last updated
2017-09-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

rosacea

Interventions

experimental group:30% new supramolecular salicylic acid
Minocycline.

Sponsors

The Second Affliated Hospital of Xi'an Jiaotong University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. Diagnosed of having erythematotelangiectatic and papulopustular rosacea by the NRSEC diagnostic criteria; 2. Agreed to the split-face study ,male or female aged 18 to 60 years; 3. Signed the informed consent.

Exclusion criteria

Exclusion criteria: 1. Allergic to any ingredients of the study drugs; 2. Diagnosed of having an acute inflammation on the face; 3. Patients with poor compliance; 4. Currently on other treatment for rosacea.

Design outcomes

Primary

MeasureTime frame
symptom score;erythema index;TEWL;melanin index;—

Secondary

MeasureTime frame
patient satisfaction;—

Countries

China

Contacts

Public ContactShujuan He

The Second Affliated Hospital of Xi'an Jiaotong University

hsjhsjsxzj@163.com+86 18220187933

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026